Product Details
| Product Name:
Piritrexim |
CAS No.:
72732-56-0 |
| Purity:
99.29% |
Supply Ability:
10g |
| Release date:
2026/05/11 |
Product Introduction
Bioactivity
| Name | Piritrexim |
| Description | Piritrexim (BW 301U) is an orally available fat-soluble dihydrofolate reductase inhibitor with pulmonary toxicity used in the study of uroepithelial carcinoma and metastatic breast cancer. |
| In vitro | Piritrexim (0.1 to 1.0 microM) was able to inhibit the replication of T.gondii in a mouse peritoneal macrophage model. The addition of sulfadiazine, which alone was ineffective, to piritrexim allowed inhibition of T.gondii replication at lower concentrations of piritrexim than when piritrexim was used alone.[5] |
| In vivo | Piritrexim (25-mg/m2/dose; oral) occurred the myelosuppression and mucositis in 4 of 4 patients but in none of the patients treated at the 15- and 20-mg/m2/dose levels.[6]
Piritrexim (20 mg/m2/dose; oral) was rapidly absorbed, with the median time to peak level occurring 1.5 h after an oral dose, and the area under the concentration-time curve (AUC) was linearly related to the dose administered. Trough plasma piritrexim concentration strongly correlated with DLT (P = 0.0016). A trough plasma piritrexim concentration greater than 0.5 microM appeared to be predictive of toxicity. Eleven of 15 patients with trough concentrations exceeding this threshold experienced DLTs.[6] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Keywords | Piritrexim | DHFR |
| Inhibitors Related | Pemetrexed | Epiroprim | Urea | Methotrexate metabolite | Trimethoprim | Diaveridine | DS44960156 | Gentamicin sulfate | LY 345899 | Methotrexate Diglutamate | WR99210 hydrochloride(47326-86-3 free base) | Sulfameter |
| Related Compound Libraries | Bioactive Compound Library | Anti-Breast Cancer Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Metabolism Compound Library | Anti-Aging Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$2500.00
|
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-05-11 |
United States